Funded Biotechnology Startups in Amsterdam
Within this Amsterdam biotechnology set of 12 rows, the largest disclosed round is VectorY’s $138M on 2023-11-13.
Within this Amsterdam biotechnology set of 12 rows, the largest disclosed round is VectorY’s $138M on 2023-11-13. That amount dwarfs the rest of the disclosed rounds, where multiple entries cluster at much lower figures such as $35M (Leyden Labs, 2025-10-04), $31M (Scenic Biotech, 2022-03-10), $22M (LUMICKS, 2024-10-10), and $7M (NLC, 2024-06-03). On the stage side, disclosed “Seed” rounds recur (PayEye $4M on 2022-10-20; Lapsi Health $4M on 2023-11-10), while “Series Unknown” appears frequently, spanning both multi-million rounds like Confocal.nl’s $5M (2024-10-17) and higher disclosed funding such as Leyden Labs’ $35M (2025-10-04).
Temporal and “disclosure” patterns are also noticeable: 7 of 12 entries are dated 2023-11 to 2023-06, with a dense mid/late-2023 cluster that includes VectorY ($138M, 2023-11-13), RespiQ ($4M, 2023-11-20), and Lapsi Health ($4M, 2023-11-10). The rows span 2022-03-10 (Scenic Biotech) through 2025-10-28 (Scinvivo), and disclosure is mixed—4 of the 12 entries list “undisclosed” amounts (Scinvivo 2025-10-28; Genewity B.V. 2023-06-23; Xinvento 2022-04-21) rather than a dollar figure.
Most recent rounds
12 shownRelated listings
Frequently asked
What is the largest disclosed funding round here, and how does it compare to the next-highest disclosed rounds?
VectorY’s disclosed $138M on 2023-11-13 is an outlier in this list. The next-largest disclosed amounts are $35M (Leyden Labs, 2025-10-04) and $31M (Scenic Biotech, 2022-03-10), with most other disclosed entries below $22M (e.g., LUMICKS $22M on 2024-10-10, Confocal.nl $5M on 2024-10-17).
How concentrated are the rounds in time among these 12 Amsterdam biotech entries?
There is a clear mid/late-2023 concentration: 5 of the 12 rows fall between 2023-11-10 and 2023-11-20 (Lapsi Health $4M on 2023-11-10; VectorY $138M on 2023-11-13; RespiQ $4M on 2023-11-20; plus Lapsi’s and VectorY’s same-month proximity). The overall window runs from 2022-03-10 (Scenic Biotech) to 2025-10-28 (Scinvivo).
Are there disclosure/staging patterns that stand out across the list?
Disclosure is mixed: 3 entries are explicitly “undisclosed” with no dollar amount (Scinvivo on 2025-10-28; Genewity B.V. on 2023-06-23; Xinvento on 2022-04-21). Among disclosed amounts, “Seed” shows up more than once at the same disclosed level ($4M for PayEye on 2022-10-20 and $4M for Lapsi Health on 2023-11-10), while “Series Unknown” is common (e.g., Confocal.nl $5M on 2024-10-17; LUMICKS $22M on 2024-10-10).
Does the list skew toward particular funding stages based on the named rounds?
Two named stages appear repeatedly while others are singletons: “Seed” occurs for PayEye (Seed, $4M on 2022-10-20) and Lapsi Health (Seed, $4M on 2023-11-10). “Series A” occurs twice as well, with Scenic Biotech at $31M on 2022-03-10 and VectorY at $138M on 2023-11-13, whereas most other entries are labeled “Series Unknown” (e.g., NLC $7M on 2024-06-03).
Are any companies or rounds worth flagging as unusually small among the disclosed amounts?
Among disclosed figures, the smallest amount in the dataset is $4M, appearing multiple times rather than as a single one-off: RespiQ ($4M, 2023-11-20), Lapsi Health ($4M, 2023-11-10), and PayEye ($4M, 2022-10-20). That stands in contrast to VectorY’s $138M (2023-11-13), which is materially higher than all other disclosed amounts in this list.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.